Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-3774
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience ; day:16 ; month:8 ; year:2022 ; pages:1-7
International journal of hematology ; (16.8.2022), 1-7
- Creator
-
Spałek, Adrianna
Wieczorkiewicz-Kabut, Agata
Koclęga, Anna
Woźniczka, Krzysztof
Węglarz, Patryk
Boral, Kinga
Kata, Dariusz
Zielińska, Patrycja
Helbig, Grzegorz
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12185-022-03434-5
- URN
-
urn:nbn:de:101:1-2022110318325470448594
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Spałek, Adrianna
- Wieczorkiewicz-Kabut, Agata
- Koclęga, Anna
- Woźniczka, Krzysztof
- Węglarz, Patryk
- Boral, Kinga
- Kata, Dariusz
- Zielińska, Patrycja
- Helbig, Grzegorz
- SpringerLink (Online service)
Other Objects (12)
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Fecal microbiota transfer for refractory intestinal graft-versus-host disease — experience from two German tertiary centers
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Fecal microbiota transfer for refractory intestinal graft-versus-host disease — experience from two German tertiary centers
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Fecal microbiota transfer for refractory intestinal graft-versus-host disease — experience from two German tertiary centers
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD